Literature DB >> 2605948

Calcium phosphate mineralization.

G H Nancollas1, S J Zawacki.   

Abstract

Although it is often assumed that the thermodynamically most stable hydroxyapatite is a suitable prototype for biological minerals, it is now generally accepted that other phases such as dicalcium phosphate dihydrate and octacalcium phosphate as well as defect apatites and carbonated apatites may participate. The Constant Composition kinetics method, has been used to show that defect apatites may be formed with non-stoichiometric coefficients that depend upon the pH of the growth medium. Important factors in analyzing these experiments are the initial surface modification and ion exchange processes involving hydrogen and calcium ions following inoculation of the supersaturated solutions. Proteins and other macromolecules which may inhibit the rate of growth of calcium phosphates in supersaturated solutions are able to enhance the nucleation of these phases when immobilized on inert surfaces.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605948     DOI: 10.3109/03008208909050013

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  3 in total

Review 1.  Modulation of bone calcium-binding sites regulates plasma calcium: an hypothesis.

Authors:  F Bronner; W D Stein
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

Review 2.  Biomineralization and matrix vesicles in biology and pathology.

Authors:  Ellis E Golub
Journal:  Semin Immunopathol       Date:  2010-12-08       Impact factor: 9.623

3.  Idiopathic recurrent calcium urolithiasis (IRCU): variation of fasting urinary protein is a window to pathophysiology or simple consequence of renal stones in situ? A tripartite study in male patients providing insight into oxidative metabolism as possible driving force towards alteration of urine composition, calcium salt crystallization and stone formation.

Authors:  Paul O Schwille; A Schmiedl; J Wipplinger
Journal:  Eur J Med Res       Date:  2009-09-01       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.